The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 23, 2014

Filed:

Aug. 05, 2009
Applicants:

Rafi Ahmed, Atlanta, GA (US);

Christian P. Larsen, Atlanta, GA (US);

Koichi Araki, Atlanta, GA (US);

Inventors:

Rafi Ahmed, Atlanta, GA (US);

Christian P. Larsen, Atlanta, GA (US);

Koichi Araki, Atlanta, GA (US);

Assignee:

Emory University, Atlanta, GA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/12 (2006.01); A61K 39/02 (2006.01); A61K 39/002 (2006.01); G01N 33/50 (2006.01); C07K 14/005 (2006.01); A61K 45/06 (2006.01); A61K 39/39 (2006.01); A61K 31/4745 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4745 (2013.01); C07K 14/005 (2013.01); A61K 39/12 (2013.01); C12N 2740/13013 (2013.01); A61K 45/06 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/53 (2013.01); C12N 2730/10134 (2013.01); A61K 2039/55516 (2013.01); C12N 2760/10034 (2013.01); A61K 39/39 (2013.01); C12N 2770/10022 (2013.01); A61K 2039/5258 (2013.01); C12N 2710/10343 (2013.01); C12N 2710/24122 (2013.01);
Abstract

It is disclosed herein that treatment of a subject with an mTOR inhibitor enhances antigen-specific T cell immune responses. Thus, provided herein is a method of enhancing an antigen-specific T cell response in a subject by administering to the subject a therapeutically effective amount of an mTOR inhibitor. The antigen can be any antigen, such as an antigen from a pathogen or a vaccine, or a tumor antigen. In some embodiments, the method further comprises administering to the subject a vaccine, such as a virus vaccine or a cancer vaccine. The mTOR inhibitor can be administered either before or after vaccination to enhance the quantity and quality of the T cell immune response and immunological memory. In some examples, the mTOR inhibitor is rapamycin or a rapamycin analog.


Find Patent Forward Citations

Loading…